Intermediate-dose cytarabine therapy was administered as 0.5-1.0g/m Conclusions:Intermediate-dose cytarabine is an efficient treatment option for non-Langerhans cell histiocytosis patients, especially for those with CNS involvement.doi:10.1186/s13023-022-02193-0Ting.Liu...
4) High dose cytarabine 大剂量阿糖胞苷 1. AIM:To observe the pharmacokinetics and adverse drug reaction (ADR) after high dose cytarabine maintenanced chemotherapy in 5 children with acute nonlymphocytic leukemia (ANLL). 目的:了解大剂量阿糖胞苷化疗后 ,患者的药物动力学参数及不良反应。 更多例句...
Twenty-three patients with acute non lymphocytic leukemia (ANLL), were treated with a single-6 day course of Mitoxantrone 6mg/m2/day, Etoposide 80mg/m2/day and intermediate dose Cytarabine (ara-C) 1g/m2/day (MEC). Patients who achieved complete remission (CR) were submitted to a 4-day-...
In this study,we compared the efficacy of mitoxantrone in combination with intermediate-dose cytarabine(HAM) with that of high-dose cytarabine alone(Hi DAC) as consolidation regimens in non-acute promyelocytic leukemia(APL) acute myeloid leukemia patients with favorable and intermediate cytogenetics.A ...
Comparison of allogeneic stem cell transplantation, high-dose cytarabine, and autologous peripheral stem cell transplantation as postremission treatment in patients with de novo acute myelogenous leukemia. Cancer-Am Cancer Soc. 2003;97(7):1721–31. CAS Google Scholar Breems DA, Boogaerts MA, Dekker...
Ohno, R.et al.(1990). Intensive Induction Therapy with Behenoyl, Cytosine Arabinoside, Daunorubicin, and 6-Mercaptopurine Followed by Intensive Consolidation with Mitoxantrone, Etoposide, Vincristine, and Intermediate-Dose Continuous Cytarabine (M-85 Protocol) for Adult Acute Myelogenous Leukemia. In: ...
Mantovani L, Hasenclever D, Krahl R, Ponisch W, Herold M, Pasold R, Fiedler F, Dolken G, Kampfe D, Schmoll HJ et al (2002) Intermediate-dose cytarabine treatment delivered at moderate infusion rates for de novo acute myeloid leukemia-results of a phase I-II study. Leuk Lymphoma 43:...
However, high-dose cytarabine (HIDAC) regimens correlate with increased morbidity and toxicity related mortality. Typical HIDAC regimens deliver 6 g/m 2 /d in infusion rates of 500-3000 mg/m 2 /h. However, pharmacokinetic measurements indicate that intracellular Ara-CTP formation is saturated at...
CytarabineDe novoModerate infusion ratePublished randomized trials on different cytarabine doses for the treatment of acute myeloid leukemia (AML) provide evidence of a dose-response effect. However, high-dose cytarabine (HIDAC) regimens correlate with increased morbidity and toxicity related mortality. ...
2) High dose cytarabine 大剂量阿糖胞苷 1. AIM:To observe the pharmacokinetics and adverse drug reaction (ADR) after high dose cytarabine maintenanced chemotherapy in 5 children with acute nonlymphocytic leukemia (ANLL). 目的:了解大剂量阿糖胞苷化疗后 ,患者的药物动力学参数及不良反应。 更多例句...